Trial · NCT07001540
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
NCT07001540, Phase 2, Recruiting, Fudan University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation. Trials, record NCT07001540. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07001540
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
- NCT number
- NCT07001540
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 130 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)
- First posted
- 2025-06-03
- Last updated
- 2025-06-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Invetigator-assessed Objective Response Rate (ORR) | Assessed up to 3 years | Defined as the proportion of all analyzable subjects achieving complete response (CR) and partial response (PR) after study initiation. |
| Secondary | The CR rate assessed by the investigator | Assessed up to 3 years | Defined as the proportion of all analyzable subjects achieving complete response (CR) after study initiation. |
| Secondary | Event-free survival (EFS) | Assessed up to 3 years | Defined as the time from the start of treatment to disease progression/recurrence, death from any cause, or the start of next line lymphoma therapy (NALT); Patients who had not experienced an event at the time of analysis were excluded from the most recent disease assessment date. |
| Secondary | 24-month progression-free survival (PFS) rate | Assessed up to 24 months | PFS is defined as the time between the start of treatment and first recording to disease progression or death; Patients who had not experienced an event at the time of analysis were excluded from the most recent disease assessment date. |
| Secondary | Overall survival time (OS) | Assessed up to 15 years | Defined as the time from the start of treatment until death from any cause; Patients who had not experienced an event at the time of analysis were deleted on the date the patient was last known to be alive. |
| Secondary | Security | Assessed up to 3 years | The incidence of adverse events (AES), defined as all adverse events that occurred after a patient received the investigatory treatment regimen; The incidence of treatment-related AES was defined as the incidence of AEs associated with salvage therapy, transplantation, and consolidation therapy considered by the investigator after a patient received the investigational treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07001540
GET https://conductscience.org/api/trials/v1/NCT07001540/registered